DE20212933U1 - Vitamin- und Spurenelemente-Mischung für Nierenkranke - Google Patents

Vitamin- und Spurenelemente-Mischung für Nierenkranke

Info

Publication number
DE20212933U1
DE20212933U1 DE20212933U DE20212933U DE20212933U1 DE 20212933 U1 DE20212933 U1 DE 20212933U1 DE 20212933 U DE20212933 U DE 20212933U DE 20212933 U DE20212933 U DE 20212933U DE 20212933 U1 DE20212933 U1 DE 20212933U1
Authority
DE
Germany
Prior art keywords
vitamin
mixture
trace element
substances according
element mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE20212933U
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE20212933U priority Critical patent/DE20212933U1/de
Publication of DE20212933U1 publication Critical patent/DE20212933U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof

Description

Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt

Claims (6)

1. Substanzgemisch zur oralen Einnahme, dadurch gekennzeichnet, dass in einer Tagesportion enthalten sind:
Vitamin B1 1,5-5,0 mg (vorzugsweise 3,0 mg)
Vitamin B2 1,5-5,0 mg (vorzugsweise 3,0 mg)
Vitamin B6 6,0-12,0 mg (vorzugsweise 10,0 mg)
Vitamin B12 3,0-8,0 µg (vorzugsweise 6,0 µg)
Vitamin C 60-200 mg (vorzugsweise 100 mg)
Vitamin E 30-100 IE (vorzugsweise 50 IE)
Biotin 50-200 µg (vorzugsweise 100 µg)
Folsäure 600-1500 µg (vorzugsweise 800 µg)
Nicotinamid 10-30 mg (vorzugsweise 20,0 mg)
Pantothensäure 5-20 mg (vorzugsweise 10,0 mg)
Selen 20-60 µg (vorzugsweise 30,0 µg)
Zink 10-30 mg (vorzugsweise 15,0 mg).
2. Substanzgemisch nach Anspruch 1, dadurch gekennzeichnet, dass zusätzlich enthalten sind: Vitamin K 50-150 µg (vorzugsweise 70 µg).
3. Substanzgemisch nach Anspruch 1-2, dadurch gekennzeichnet, dass zusätzlich enthalten sind: L-Carnitin 50-200 mg (vorzugsweise 100 mg).
4. Substanzgemisch nach Anspruch 1-3, dadurch gekennzeichnet, dass das Verhältnis von Vitamin C zu Vitamin E = 2 zu 1 beträgt.
5. Substanzgemisch nach Anspruch 1-4, dadurch gekennzeichnet, dass die Darreichungsform eine Tablette, Dragee, Kapsel, Pulver oder Granulat sein kann.
6. Substanzgemisch nach Anspruch 1-5, dadurch gekennzeichnet, dass es als Arzneimittel, diätetisches Lebensmittel für besondere medizinische Zwecke oder Nahrungsergänzungsmittel angeboten werden kann.
DE20212933U 2002-08-19 2002-08-19 Vitamin- und Spurenelemente-Mischung für Nierenkranke Expired - Lifetime DE20212933U1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE20212933U DE20212933U1 (de) 2002-08-19 2002-08-19 Vitamin- und Spurenelemente-Mischung für Nierenkranke

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE20212933U DE20212933U1 (de) 2002-08-19 2002-08-19 Vitamin- und Spurenelemente-Mischung für Nierenkranke

Publications (1)

Publication Number Publication Date
DE20212933U1 true DE20212933U1 (de) 2002-11-21

Family

ID=7974345

Family Applications (1)

Application Number Title Priority Date Filing Date
DE20212933U Expired - Lifetime DE20212933U1 (de) 2002-08-19 2002-08-19 Vitamin- und Spurenelemente-Mischung für Nierenkranke

Country Status (1)

Country Link
DE (1) DE20212933U1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379172A (zh) * 2012-06-28 2015-02-25 株式会社明治 营养组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379172A (zh) * 2012-06-28 2015-02-25 株式会社明治 营养组合物

Similar Documents

Publication Publication Date Title
US20090304602A1 (en) Nutritional supplement
CA2097196A1 (en) Enteral preparation for cancer therapy
US11957650B2 (en) Formulation and method for the prevention and/or treatment of hangover symptoms
US6447818B1 (en) Compositions containing compounds with adrenergic activity and vegetable extracts of Crataegus and gingko biloba for the treatment of overweight and obesity
EP0305097B1 (de) Nahrungsmittelzusatz
ES2271042T3 (es) Suplemento alimenticio con un efecto adelgazante.
CA2305190A1 (en) Serotonin containing formulation for oral administration and method of use
DE20212933U1 (de) Vitamin- und Spurenelemente-Mischung für Nierenkranke
CN105168846A (zh) 一种具有生理功能的口服组合物
JP2019532098A (ja) 腎臓透析を受けている患者のための食餌性多量／微量栄養補給剤
Kenny et al. Clinical zinc deficiency during adequate enteral nutrition.
Shah Iron deficiency anemia-Part III
CA2518738A1 (en) Method and composition for preventing or reducing diarrhea
US7390513B2 (en) Food supplement formulation
JP5241127B2 (ja) 鎮痛用組成物
EP3842038A1 (de) Mikroenkapsulierte formulierung aus eisen und zystein
Vazquez Comparing oxandrin and anadrol-50
WO2000007463A1 (en) Multi-vitamin and mineral supplements for women
NL2018302B1 (nl) Samenstelling voor toepassing in de behandeling en / of preventie van een tekort aan vitaminen, mineralen en/of sporenelementen.
Rossetti Single-shot vs conventional therapy with amikacin for treatment of uncomplicated urinary tract infections: a multicenter study
RU2155059C1 (ru) Биологически активная добавка, обладающая адаптогенной активностью
Hoerr et al. Ginkgo biloba and usage in dementia: from Eastern tradition to Western science
Coulter Vitamin and Antioxidant Protocols in HIV Disease
Wu et al. Cytotoxic activity of FK973 against human oral and breast cancer cells
CA2602037C (en) Indicator for orally administered compositions

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20030102

R163 Identified publications notified

Effective date: 20030314

R150 Term of protection extended to 6 years

Effective date: 20050425

R157 Lapse of ip right after 6 years

Effective date: 20090303